雷帕鸣用药注意事项

(Sirolimus tablets) was approved by the US FDA for official marketing in September 1999. Sirolimus is mainly used to prevent and treat rejection of kidney, liver and other transplants, and is especially suitable for patients with renal dysfunction, tremor and hypertension. Rapamide has low oral bioavailability, large inter-individual pharmacokinetic (PK) differences, and is a substrate of CYP3A and P glycoprotein (PgP), which can cause drug-drug interactions with a variety of drugs.

Rapamide has remarkable therapeutic effects, and the successful development of this drug is good news for many patients. However, the price of the original drug Rapamin is relatively high, which is a big burden for patients who need to take the drug for long-term treatment. Many patients choose India's Biocon Repamin. Biocon India, one of India's top three biotech companies, is an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and partners to provide affordable healthcare solutions by leveraging India's cost advantages and autoimmune disease patients and healthcare systems around the world.

Precautions for use of India's Biocon Repamin:

Treatment with Rapamune may cause infection. Immunosuppression may also increase the risk of infection, including activation of latent viral infections (including BK virus-related nephropathy), fatal infections, and sepsis. Therefore, patients should be promptly evaluated for any neurological changes during treatment with rapamycin; consider reducing the degree of immunosuppression in transplant patients and taking into account the risk of organ rejection.

Treatment with Rapamune may cause interstitial lung disease: Cases of interstitial lung disease (such as pneumonia, bronchiolitis obliterans, organizing pneumonia, pulmonary fibrosis, etc.) have been observed; may be associated with pulmonary hypertension (including pulmonary hypertension). ILD can be relieved by reducing the dose or discontinuing treatment.

Treatment with Rapamune may increase blood lipids (cholesterol and triglycerides). Use with caution in patients with hyperlipidemia. Monitor cholesterol/lipids; if hyperlipidemia occurs, follow current management guidelines (diet, exercise, lipid-lowering agents). Antihyperlipidemic treatments may not be effective in achieving normal levels.

Recommended related hot articles: /newsDetail/86920.html